Ng, M., Emmanuela Gakidou, Lo, J., Abate, Y.H., Cristiana Abbafati, Abbas, N., Mohammadreza Abbasian, Samar Abd ElHafeez, Abdel-Rahman, W.M., Sherief Abd-Elsalam, Abdollahi, A., Meriem Abdoun, Abdulah, D.M., Rizwan Suliankatchi Abdulkader, Abdullahi, A., Abedi, A., Hansani Madushika Abeywickrama, Alemwork Abie, Aboagye, R.G
These decisions depend on the previous drug, current dose, side effects, glucose readings, and the new products label
Figure III in the Data Supplement)
Dosage information from clinical trials Any discussion of retatrutide dosing must start with a critical disclaimer
[10] [4] It is important to note that the specific combination of cagrilintide with retatrutide as a co-administered regimen is entirely hypothetical at this stage